{"id":15540,"date":"2011-08-01T11:05:33","date_gmt":"2011-08-01T11:05:33","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=15540"},"modified":"2013-01-30T13:28:23","modified_gmt":"2013-01-30T13:28:23","slug":"fda-approve-new-nnrti-based-fixed-dose-combination-of-rilpivirinetenofovirftc-complera-in-the-us","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/15540","title":{"rendered":"FDA approve new NNRTI-based fixed dose combination of rilpivirine\/tenofovir\/FTC (Complera) in the US"},"content":{"rendered":"<p>On 10 August 2011, US Food and Drug Administration (FDA) approved a fixed-dose combination of rilpivirine\/tenofovir\/FTC (Complera) with an indication in treatment-naive adults. This is a single-tablet once-daily combination.<\/p>\n<p>Approval was based on bioequivilence to the individual drugs taken separately, together with the phase 3 registrational studies for rilpivirine (ECHO and THRIVE) &#8211; see <a href=\"https:\/\/i-base.info\/htb\/15538\">FDA approve rilpivirine in the US<\/a>.<\/p>\n<p>References<\/p>\n<p>US\u00a0Food\u00a0and\u00a0Drug\u00a0Administration\u00a0approves\u00a0Gilead\u00a0sciences\u0092 Complera,\u00a0a new\u00a0complete once-daily, single-tablet\u00a0regimen\u00a0for\u00a0HIV-1\u00a0infection\u00a0in\u00a0treatment-naive adults. Gilead press release. (10 August 2011).<\/p>\n<p><a href=\"http:\/\/www.gilead.com\/pr_1595280\">http:\/\/www.gilead.com\/pr_1595280<\/a><\/p>\n<p>Prescribing information<\/p>\n<p><a href=\"http:\/\/www.gilead.com\/pdf\/complera_pi.pdf\">http:\/\/www.gilead.com\/pdf\/complera_pi.pdf<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>On 10 August 2011, US Food and Drug Administration (FDA) approved a fixed-dose combination of rilpivirine\/tenofovir\/FTC (Complera) with an indication in treatment-naive adults. This is a single-tablet once-daily combination. Approval was based on bioequivilence to the individual drugs taken separately, &hellip;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"class_list":["post-15540","post","type-post","status-publish","format-standard","hentry","category-antiretrovirals"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/15540","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=15540"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/15540\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=15540"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=15540"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=15540"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}